Document Detail


Etanercept enhances preservation of osteochondral allograft viability.
MedLine Citation:
PMID:  21389186     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Osteochondral allografts are an increasingly popular treatment for the repair of articular cartilage lesions. Current tissue bank protocols require bacteriological testing that takes from 21 to 28 days to process. During this time, tumor necrosis factor-alpha (TNF-α, a proapoptotic cytokine) is upregulated, resulting in loss of chondrocyte viability. To date, etanercept (a cytokine inhibitor) has not been studied in the current storage paradigm with the intention of preserving cell viability.
PURPOSE: This study was undertaken to assess whether the addition of etanercept can improve the chondrocyte viability ofosteochondral allograft during storage.
STUDY DESIGN: Controlled laboratory study.
METHODS: Osteochondral allografts were harvested from 8 Boer goat femurs and placed into storage media and stored at 4°C for 28 days. The experimental group was supplemented with 10 µg/mL of etanercept. After storage, cell viability was assessed by live/dead staining and confocal microscopy. Specimens were also analyzed histologically and underwent histomorphologic analysis. TNF-α expression was measured with semiquantitative polymerase chain reaction.
RESULTS: At 28 days, the percentage viability of the superficial zone in etanercept-treated allografts was maintained at significantly higher levels than those measured in the untreated group (69.3 ± 9.4 compared with 47.8 ± 19.1, P = .01). No difference was found histologically between the etanercept and the untreated group (ie, safranin O staining for glycosaminoglycan expression). Histomorphologic assessment showed no difference in indentation stiffness or roughness between groups. TNF-α expression was significantly decreased in the etanercept group compared to the untreated group.
CONCLUSION: Etanercept was able to maintain cell viability of osteochondral allografts significantly better than the current storage paradigm after 28 days of storage.
CLINICAL RELEVANCE: Maintaining the viability of the superficial zone will benefit outcomes by facilitating joint articulation via improved lubrication. Additionally, maintaining the cellular viability for increased periods of time may allow a greater window of time in which a suitable recipient may be found.
Authors:
Michael S Linn; Derek C Chase; Robert M Healey; Frederick L Harwood; William D Bugbee; David Amiel
Related Documents :
21109076 - Esterified hyaluronic acid improves cartilage viability in experimental tracheal recons...
19204026 - Therapeutic efficacy of unilateral subthalamotomy in parkinson's disease: results in 89...
21163586 - High-dose-rate brachytherapy boost for prostate cancer: comparison of two different fra...
10928576 - The use of dopamine agonists in very elderly patients with parkinson's disease.
10733826 - Favorable long-term results with the end-to-side jejunoileal bypass.
15675136 - Churg strauss syndrome--successful induction of remission with methotrexate and unexpec...
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't     Date:  2011-03-09
Journal Detail:
Title:  The American journal of sports medicine     Volume:  39     ISSN:  1552-3365     ISO Abbreviation:  Am J Sports Med     Publication Date:  2011 Jul 
Date Detail:
Created Date:  2011-07-06     Completed Date:  2011-12-09     Revised Date:  2014-09-11    
Medline Journal Info:
Nlm Unique ID:  7609541     Medline TA:  Am J Sports Med     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1494-9     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Anti-Inflammatory Agents, Non-Steroidal / pharmacology*
Cell Culture Techniques / methods
Cell Survival / drug effects
Chondrocytes / cytology*,  drug effects*
Glycosaminoglycans / metabolism
Goats
Immunoglobulin G / pharmacology*
Receptors, Tumor Necrosis Factor
Time Factors
Tissue Preservation / methods*
Tumor Necrosis Factor-alpha / antagonists & inhibitors*
Grant Support
ID/Acronym/Agency:
AR55637/AR/NIAMS NIH HHS; R01 AR055637/AR/NIAMS NIH HHS; R01 AR055637-03/AR/NIAMS NIH HHS
Chemical
Reg. No./Substance:
0/Anti-Inflammatory Agents, Non-Steroidal; 0/Glycosaminoglycans; 0/Immunoglobulin G; 0/Receptors, Tumor Necrosis Factor; 0/Tumor Necrosis Factor-alpha; 185243-69-0/TNFR-Fc fusion protein
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  A Prospective Study of Snowkiting Injuries.
Next Document:  Suppression of the uPAR-uPA System Retards Angiogenesis, Invasion and in vivo Tumor Development in P...